Gleiss Lutz has advised Danish pharma company Leo Pharma on its acquisition of the global dermatology portfolio from Japanese pharmaceuticals manufacturer Astellas Pharma Inc. The deal is worth EUR 675 million. Closing of the transaction is still subject to approval by the antitrust authorities and expected during the first quarter of 2016.
Global pharmaceuticals company Leo Pharma A/S headquartered in Ballerup, Denmark, specialises in dermatology products. Its takeover of the Astellas’ dermatology business represents Leo Pharma’s largest acquisition to date. The move, which is part of the company’s global expansion strategy aimed at becoming the preferred dermatology care partner in the world, will increase Leo Pharma’s annual turnover by approx. 20%.
Leo Pharma was advised by the following team of Gleiss Lutz lawyers: Dr. Jan Bauer (partner, lead, Frankfurt), Dr. Martin Viciano Gofferje (counsel, Berlin), Bernhard C. Barth (Berlin) (all corporate/M&A), Dr. Ingo Brinker (partner) and Dr. Iris Benedikt-Buckenleib (both competition/antitrust, Munich).
Law firm Kromann Reumert advised on aspects of Danish law.
Forward
